Background: Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse. Aim: To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome. Methods: This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control. Results: Of 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%. Conclusions: Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).
Introduction
Neuroendocrine tumours (NETs) represent a heterogeneous group of neoplasms, arising from neuroendocrine cells of the endocrine system [1] . They can develop in almost any organ, but occur most frequently in the lung, pancreas and gastrointestinal tract [2] . NETs can be silent (non-functioning) or clinically symptomatic (functioning). The latter are characterized by the secretion of peptides and neurotransmitters; this, in turn, leads to the development of typical clinical syndromes [3, 4] . For example, some NETs release peptides and amines (e.g. serotonin), which produce a characteristic set of symptoms called carcinoid syndrome (CS) [3, 4] . CS occurs in approximately 10% of patients with metastatic NETs [4] and is most prevalent in those with NETs of the small intestine (∼20%) [3] . The predominant symptoms of CS are flushing (90%), diarrhoea (70%), and abdominal pain (40%) [3] . These can be very distressing for patients and have a negative impact on health-related quality of life (QoL) [5] .
Surgery remains the only curative treatment for NETs presenting with early disease or metastatic disease amenable to curative resection [6] ; if this is not possible, locoregional treatment of hepatic metastases for selected patients has been advocated [7] . Currently approved systemic treatments to control tumor growth in patients with midgut NETs are limited to somatostatin analogues (SSAs) [6] [7] [8] .
Depot formulations of SSAs are currently considered the 'standard of care' for symptom control in CS [9] ; these include lanreotide (Somatuline ® ) Autogel (Depot in the US), which is administered by deep subcutaneous injection, and octreotide (Sandostatin ® ) LAR ® , which is administered intramuscularly. SSAs such as lanreotide are available in Europe and several other countries for the treatment of CS, supported by clinical experience and clinical studies [9] [10] [11] [12] [13] . Most recently, a large international Phase III study, ELECT, which was conducted in Europe and the US, demonstrated statistically significant symptom relief with lanreotide based on reduced use of a short-acting SSA [14] .
In addition, there is evidence for SSAs as antitumour treatment. In particular, a large, international, Phase III study, CLARINET has demonstrated anti-tumour effects with lanreotide for metastatic G1 and G2 NET including midgut tumours [15] . A phase III study, PROMID, also showed anti-tumour effects with octreotide in a smaller population of metastatic G1 midgut NET patients [16] . Peptide receptor radio-targeted therapy with radiolabelled SSAs, which is used more commonly in Europe, may also have therapeutic potential in NETs. Recently, a phase III study, NETTER-1, showed that 177-Lu-Dotatate combined with a standard dose of SSA versus a high dose SSA alone was associated with a significant improvement in progression-free survival in patients with progressive midgut NETs [17] .
To date, only a small number of NET clinical studies have examined both patient-reported outcomes (PROs) and QoL measures with current NET treatments [18] . These have mainly been studies of SSAs and peptide receptor radio-targeted therapies, which have shown treatment was associated with stable or improved QoL outcomes in patients [11, [13] [14] [15] 19] . Most recently, the phase III TELESTAR study of telotristat etiporate, a serotonin synthesis inhibitor under development, showed significant reductions in bowel movements in patients with CS inadequately controlled with SSA, which was associated with treatment satisfaction and perceived symptom relief reported by a subset of patients interviewed after treatment [20] . However, no large prospective clinical studies have focused specifically on the impact of NET treatment on patient-reported satisfaction with symptom control in a large CS patient population.
Here, we present the results of SymNET, a large multinational observational study of the real-world patient experience of CS symptom management at a single routine clinic visit at a number of specialist centres. The main focus of the study was to evaluate a number of PRO measures -including the primary endpoint, patient satisfaction with diarrhoea control -in NET patients who had received lanreotide Autogel/Depot. The study also evaluated medical records of physician-recorded CS symptoms and other patient characteristics at lanreotide initiation and at the clinic visit in order to explore their relationship with patient satisfaction.
Methods

Patients
Adult patients (≥18 years) diagnosed with an NET were eligible if they had been receiving lanreotide Autogel/Depot for >3 months for relief of symptoms associated with CS, as indicated in their medical records. In particular, all patients were required to have a history of diarrhoea related to CS. Investigators were required to recruit all consecutive eligible and consenting patients in order to avoid recruitment bias.
Patients had to provide written informed consent to allow their medical data to be collected, analyzed, and shared with regulatory authorities.
Trial design and interventions
SymNET was a multinational, observational, non-interventional study conducted between October 2010 (first patient enrolled) and December 2012 (last patient visit) at 45 secondary or tertiary care centres in eight countries (Czech Republic, France, Hungary, Israel, Italy, Poland, Spain, and UK) (ClinicalTrials.gov: NCT01234168). Patient recruitment and PRO assessment were conducted prospectively during a single study visit; in addition, patient data were collected from medical records.
The study did not impact on usual clinical management. Patients' clinic attendance and the exact prescription of lanreotide or any other concomitant medications was unrestricted and in accordance with routine clinical practice. The decision to prescribe lanreotide was made prior to, and independently from, the decision to enrol patients in the present study.
The conduct of the study was in accordance with Good Pharmacoepidemiological Practice Guidelines from the International Society for Pharmacoepidemiology, and local regulatory requirements for non-interventional studies. The study was approved by independent ethics committees/institutional review boards.
Assessments and endpoints
Patient-reported outcomes
During a routine clinic visit (assessment visit), patients were asked by the physician to complete questionnaires. The primary endpoint was (i) patient-reported satisfaction with diarrhoea control (PSD) on the day of the visit. Secondary endpoints also collected on day of visit included; (ii) diarrhoea severity and associated impact on daily activities (assessed using a scale derived from the clinical global impression of severity [CGI-S] scale); (iii) overall change in diarrhoea symptoms at the time of the visit compared with before treatment initiation (assessed using the patient global impression of change [PGIC] scale); (iv) patient-reported feelings and consequences of diarrhoea on daily life; (v) patient-reported satisfaction with flushing control (PSF); and (vi) QoL evaluated using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-G.I.NET 21 questionnaires. See full details of questionnaires in Supplementary Table S1 .
Patient satisfaction with control of CS symptoms other than diarrhoea and flushing was not measured as the primary focus was diarrhoea control, and only limited numbers of patients enrolled with other lesser symptoms.
Medical record review
During the assessment visit, as part of the routine consultation, physicians reviewed patients' medical records for information on demographics, disease characteristics, treatment characteristics, and diarrhoea and other CS symptoms at lanreotide initiation. Physicians also collected information on patients' diarrhoea and other CS symptoms at study visit (this was used to determine physician recorded changes in diarrhoea and other CS symptoms between lanreotide initiation and study visit). Adverse drug reactions were required to be reported to the manufacturer in accordance with standard procedures for clinical practice. No safety cases were reported as arising.
Statistical analyses
Estimated sample size, based on an anticipated PSD of 60% and precision of 5.5%, was 305 patients, assuming a two-sided 95% confidence interval (CI). For PSD-associated factors, assuming alpha = 5% and power = 80%, estimated sample size was 323 patients to detect an odds ratio (OR) ≥2 and a probability of exposure to any given level of a prognostic factor of ≥0.5. In order to ensure 323 evaluable subjects, 340 were to be included in the study. However, because of slow recruitment, the protocol was amended to reduce patient numbers and enrolment ended in December 2012, at which point >80% of the target number (i.e., >250 patients) had been enrolled (see Supplementary Information for protocol  amendments) .
The primary analysis population was all patients who were enrolled, provided consent and had data available for the relevant endpoints. The primary endpoint (PSD) was also analyzed for the per-protocol (PP) population (all those enrolled with no major protocol deviations). Descriptive methods were used for all other endpoints on PRO measures or physician-recorded changes in CS symptoms. PSD-associated factors were explored first using univariate and then multivariate logistic regression analyses. Post hoc analyses were conducted to evaluate physician-recorded changes in diarrhoea characteristics according to PSD, and patient-reported QoL according to PSD. Missing data were not replaced, and all endpoints were calculated based on patients with available data.
Results
Patient disposition and characteristics
Overall, 273 patients receiving lanreotide Autogel/Depot attended the study visit and were enrolled in this study (ITT population); of these, 92% (252) Table S2 ). Note that the whole study population was selected based on a history of diarrhoea at some point prior to the study. Of those patients for whom a reason for diarrhoea was provided (n = 262), 30% (79) 
Patient-reported outcomes for carcinoid syndrome symptom control
According to the primary PRO measure PSD, 76% of patients (203/268) were 'completely' or 'rather satisfied' with diarrhoea control at study visit (Fig. 1) diarrhoea after treatment (PGIC scale) (Fig. 2a) . Proportion of patients reporting 'mild', 'minimal', or 'no diarrhoea' also increased after treatment, from 33% (90/273) to 75% (205/273) on CGI-S (Fig. 2b) . Less than one-third of patients answered with concern to various questions about their diarrhoea or its consequences on daily life (Supplementary Table S3 ). For PSF, 73% [107/147] of those patients who reported experiencing significant flushing episodes at treatment initiation were 'completely' or 'rather satisfied' with the control of flushing at study visit (Fig. 3) .
Physician-recorded changes in carcinoid syndrome symptoms
According to their medical records, patients had significantly lower daily stool frequency at study visit than at lanreotide initiation (mean [SD] Table S2 ). At the study visit, 29% of patients (75/263) were receiving other treatments for diarrhoea, compared with 35% (93/269) at the time of lanreotide initiation. There were fewer patients experiencing flushing episodes at lanreotide initiation than at study visit (Supplementary Table S2 ).
Improvements in diarrhoea frequency, stool leakage, stool urgency, and associated pain were more common among patients reporting satisfaction with diarrhoea control than in those reporting dissatisfaction or neither satisfaction nor dissatisfaction. In those who were rather/completely satisfied, for stool frequency, 78% showed improvements versus 22% who showed no change/worsening. Similarly, for stool leakage, 18% showed improvement, 75% showed no change (remaining absent), 5% showed no change (remaining present) and 3% showed worsening.
Univariate analysis of the association of patient characteristics with PSD identified nine factors that were potentially associated with better PSD (at the alpha = 0.10 level). In the multivariate analysis, statistical significance (at the alpha = 0.05 level) was only evidenced for the association of stool leakage with better PSD, while primary tumour outside of small bowel showed a trend towards an association with better PSD (Table 2) .
Patient-reported quality of life
According to the EORTC QLQ-C30 questionnaire at study visit, patients had high levels of functioning for all scales and good global QoL. Based on median scores (higher scores, worse symptoms), the most problematic symptoms were fatigue, insomnia, and diarrhoea (median [range] = 33.3 [0-100] for all three symptoms) and, to a lesser extent, pain (16.7 [0-100]); in contrast, the majority of patients had no problems with vomiting, dyspnoea, appetite loss, constipation, and financial difficulties (i.e. the median score was 0). A similar pattern among symptoms was apparent based on mean scores.
Based on the median scores for the EORTC G.I.NET 21 questionnaire at study visit, problematic symptoms were disease-related worries (44. More patients who were satisfied with diarrhoea control also reported EORTC QLQ-C30 global QoL scores as good/very good/excellent (70%, 140/200) compared with patients who were dissatisfied (39%, 7/18) or neither satisfied nor dissatisfied with diarrhoea control (48%, 22/46).
Discussion
Data from this large real-world study demonstrate that lanreotide Autogel/Depot not only improved physician-rated symptoms in patients with CS and diarrhoea, but also a variety of subjective PROs including patient satisfaction with diarrhoea and with flushing. Satisfaction rates for diarrhoea control were slightly lower in those with versus without other contributing factors to diarrhoea. It was also shown that factors associated with even better satisfaction were the presence of stool leakage and primary tumour outside the small bowel. These data were obtained in patients mostly receiving standard doses at standard dosing intervals.
PROs are an important component of monitoring drug efficacy and patient management, particularly for symptomatic conditions such as CS and functional gastrointestinal disorders [21] . The patient's point of view on their health status is highly important, can play a role in disease management decisions and its assessment has the potential to enhance patient-centred care. Indeed, PRO assessment has been advocated by regulatory authorities [22, 23] . Recent oncology clinical trials, to support clinical benefits of new treatment options, have utilized endpoints on patient preference [24] and symptom relief [25] . Furthermore, it has been established that there is a relationship between patient preference, adherence and clinical outcomes in patients with cancer [26] .
Although some previous studies have evaluated QoL in a limited way for patients with NETs treatment, including some with lanreotide showing QoL benefits [11, [13] [14] [15] 27, 28] there is a paucity of detailed studies focusing on PROs following treatment for CS. The current study, therefore, provides new and useful data. The results are consistent with, and may explain, at least in part, observations that have shown once-monthly dosing of lanreotide is associated with good patient adherence [28] and patient perception of lanreotide injection [29] . The results also underscore the utility of PROs and that future studies assessing the efficacy of treatment of CS should endeavour to include appropriate PRO endpoints.
In the current study, patients' QoL using the validated EORTC questionnaires was evaluated only at the study visit. This allows benchmarking of the QoL in the current study against previous studies, in order to support the other new PRO measures in this study, but it does not allow the treatment effect of lanreotide on QoL to be evaluated directly. The QoL scores obtained at the study visit, which were consistent with the primary endpoint PSD, were similar to those reported from previous cross-sectional QoL surveys of the general NET population [30] [31] [32] .
Within the constraints of differences in study design and measurement of outcomes, the results obtained for physician-reported control of carcinoid symptoms are broadly consistent with the findings of other studies of SSAs showing that lanreotide achieves favourable rates of symptom control [9, 11, 12, 33] . The recent ELECT study showed that lanreotide achieved significant symptom relief versus placebo based on a one-third reduction in use of rescue therapy over its 16-week double-blind phase [9] . A retrospective study of 9 years' clinical experience with lanreotide at a specialist centre reported that 94% of patients had initial symptomatic control of flushing and stool frequency, and sustained control in 54% after median follow-up of 27 months (range 7-93) [27] , which are similar to the results in the current study obtained over a median treatment duration of 10.9 months (range 3-215) [27] .
There are some important limitations that should be considered when interpreting the SYMNET study data. Firstly, the PRO measures in this study were completed only at one visit. These data were intended to provide an accurate "snapshot" of current patient experience in routine practice. They do not provide longitudinal information. Secondly, the study intended to capture experience in a general NET population in the real world, which would have variable treatment duration, dose and dosing interval for lanreotide. These results do not reflect those that would likely be observed in a more restricted and homogenous clinical study population. Finally, inter-patient and within-patient variability are inherent to subjective PROs; however, the main PRO data were corroborated by the objective data from medical records on CS symptoms and the validated QoL questionnaires. Nevertheless, the major overall strength of this study is its conduct in a large patient cohort in a real-life clinical setting, as this increases the external validity of the results.
In conclusion, lanreotide Autogel/Depot is an effective and convenient treatment for patients with NETs and associated CS. This is supported by the PRO measures of symptom control used in this study, which were consistent with physician-rated measures during the study. PRO measures were also consistent with previous clinical data.
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